RNA, Messenger
Research News and Information

Saturday, November 21, 2009

PARP1 expression in pediatric central nervous system tumors.

13 Dec 2009 BACKGROUND: Despite advances in therapy, outcome in many high-grade pediatric central nervous system (CNS) tumors remains poor. The focus of neuro-oncology research has thus turned towards identifying novel therapeutic targets. Poly(ADP-ribose) ... Read more...

Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma.

29 Nov 2009 Our previous study has suggested that the cell cycle-related kinase (CCRK) is a putative candidate oncogene in glioblastoma tumorigenesis. The potential oncogenic role of CCRK and its clinical/prognostic significance, however, in ovarian carcinoma ... Read more...

Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells.

29 Nov 2009 Overexpression of cyclooxygenase-2 (COX-2) and elevation of its derivative prostaglandin E(2) (PGE(2)) are implicated in human esophageal squamous cell carcinoma. The expression of c-Myc, an oncogenic transcription factor, is also upregulated in ... Read more...

Latest indexed articles for 'RNA, Messenger'

These are the very latest articles for this heading:

• PARP1 expression in pediatric central nervous system tumors. 13 Dec 2009
• Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma. 29 Nov 2009
• Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells. 29 Nov 2009
• Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. 29 Nov 2009
• Differential oncogenic potential of geographically distinct Helicobacter pylori CagA isoforms in mice. 29 Nov 2009
• Overexpression of low-density lipoprotein receptor and lipid accumulation in intestinal polyps in Min mice. 29 Nov 2009
• HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. 29 Nov 2009
• Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. 29 Nov 2009
• Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. 29 Nov 2009
• mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. 29 Nov 2009
• WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. 29 Nov 2009
• How does a scanning ribosomal particle move along the 5'-untranslated region of eukaryotic mRNA? Brownian Ratchet model. 15 Nov 2009
• Expression and role of CXCL10 during the encephalitic stage of experimental and clinical African trypanosomiasis. 13 Nov 2009
• Cryptosporidium parvum infection rapidly induces a protective innate immune response involving type I interferon. 13 Nov 2009
• The reduction of cell death and proliferation by p27(Kip1) minimizes DNA damage in an experimental model of genotoxicity. 13 Nov 2009
• Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. 13 Nov 2009
• Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma. 13 Nov 2009
• Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. 13 Nov 2009
• Distinct progression-associated expression of tumor and stromal MMPs in HaCaT skin SCCs correlates with onset of invasion. 13 Nov 2009
• Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. 13 Nov 2009

See a longer list of these articles.

Technical information about 'RNA, Messenger'

Definition: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.

Registry Number: 0

Descriptor UI: D012333

Alternative terms: RNA, Messenger; mRNA; Messenger RNA; RNA, Polyadenylated; Polyadenylated RNA; Poly(A)+ RNA; Poly(A) RNA; Poly(A) Tail; mRNA, Non-Polyadenylated; mRNA, Non Polyadenylated; Non-Polyadenylated mRNA; Non Polyadenylated mRNA; mRNA, Polyadenylated; RNA, Messenger, Polyadenylated; Polyadenylated mRNA; Messenger RNA, Polyadenylated; Polyadenylated Messenger RNA; RNA, Polyadenylated Messenger; Poly(A)+ mRNA;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D13.444.735.544;

Online Note: use RNA, MESSENGER (NM) to search MRNA, NON-POLYADENYLATED 1981-94, MRNA, POLYADENYLATED 1980-94, & POLY(A)+ RNA 1980-94

History Note: 65(64); MRNA, NON-POLYADENYLATED was NON-POLYADENYLATED MRNA (NM) 1981-94; MRNA, POLYADENYLATED was POLYADENYLATED MRNA (NM) 1980-94; POLY(A)+ RNA was SY to POLY(A) RNA (NM) 1980-94

Technical Notes: IM; /drug eff /ultrastruct permitted; DF: note short X ref